Mineralys Therapeutics (MLYS) Financials

Mineralys Therapeutics (NASDAQ: MLYS) remains a development-stage biotech with no product revenue yet, so the story is still centered on cash burn, balance sheet strength, and financing needs rather than operating profits. In Q1 2026, the company posted a net loss of $39.3 million, slightly worse than the $32.2 million loss in Q4 2025, but better than some of the heavier loss quarters seen in 2024. Operating cash outflow was also substantial at $39.5 million for the quarter.

What stands out most is that Mineralys still has a large liquidity cushion. As of March 31, 2026, it reported $112.8 million in cash and $533.3 million in short-term investments, for $646.1 million in liquid assets. That gives the company a significant runway even with ongoing quarterly losses and investment activity.

• Q1 2026 ended with $646.1 million in cash and short-term investments, giving the company strong near-term liquidity.
• The company generated $6.0 million in interest and investment income in Q1 2026, helping offset some operating losses.
• Balance sheet equity remained high at $638.1 million, supported by a large cash and investment base.
• The quarterly net loss of $39.3 million was not materially worse than recent quarters and remains within the historical range for this clinical-stage biotech.
• Operating expenses were lower than in some prior 2025 quarters, with $45.3 million in total operating expenses versus $51.8 million in Q4 2024.
• Mineralys reported no revenue in the quarter, which is typical for a pre-commercial biotech but means the business is still fully dependent on capital markets and future trial progress.
• Cash flow included large investment purchases and maturities, which can create volatility in quarter-to-quarter cash movement but do not necessarily reflect core operating performance.
• Common shares outstanding have risen significantly over time, reflecting repeated equity issuance to fund operations.
• Operating cash burn remains elevated, with negative $39.5 million in Q1 2026 operating cash flow.
• The company is still reporting sizable quarterly net losses, indicating it is far from profitability.
• Share issuance continues to be a meaningful funding source, which can dilute existing shareholders over time.
• Accumulated deficit/retained earnings remained deeply negative at -$496.5 million, underscoring the long history of losses.

Looking at the broader trend, Mineralys has steadily increased its cash and investment resources since 2023, largely through equity financing and investment portfolio management. In early 2024, total current assets were about $346.8 million; by Q1 2026, they had grown to $652.5 million. That is a strong balance sheet trajectory, but it comes with the expected biotech tradeoff: higher share count and continued operating losses.

For retail investors, the key takeaway is that Mineralys appears to have funding capacity for ongoing development work, but the stock’s long-term value will likely depend on clinical execution and eventual commercialization rather than near-term financial performance.